EUCRISA (crisaborole)
TOPICAL PHOSPHODIESTERASE-4 (PDE4) INHIBITORS · ATOPIC DERMATITIS
Parke-Davis Pfizer
Drug class
Topical Phosphodiesterase-4 (PDE4) inhibitors
Topical phosphodiesterase-4 (PDE4) inhibitors are a class of nonsteroidal anti-inflammatory agents formulated for direct cutaneous application. Read more about Topical Phosphodiesterase-4 (PDE4) inhibitors
3 drugs in this class 3 manufacturers
Drugs in Topical Phosphodiesterase-4 (PDE4) inhibitors
ZORYVE (roflumilast)
ANTIPSORIATICS, TOPICAL · PLAQUE PSORIASIS
ARCUTIS BIOTHER
ADQUEY (difamilast)
TOPICAL PHOSPHODIESTERASE-4 (PDE4) INHIBITORS · ATOPIC DERMATITIS
ACROTECH BIOPHA
Filter & compare in the drug finder →
Opens the drug finder with Topical Phosphodiesterase-4 (PDE4) inhibitors preselected. Add indication or manufacturer filters there.
Topical phosphodiesterase-4 (PDE4) inhibitors are a class of nonsteroidal anti-inflammatory agents formulated for direct cutaneous application.
They function by selectively inhibiting the intracellular PDE4 enzyme, which prevents the degradation of cyclic adenosine monophosphate (cAMP) and leads to elevated intracellular cAMP levels in immune cells and keratinocytes.
This signaling cascade downstream downregulates the production of key proinflammatory cytokines, chemokines, and mediators that drive chronic cutaneous inflammation.
Approved members of this class include crisaborole and roflumilast, which are primarily utilized for the management of inflammatory dermatologic disorders, notably mild-to-moderate atopic dermatitis, plaque psoriasis, and seborrheic dermatitis.
-
nationaleczema.org
Topical phosphodiesterase-4 (PDE4) inhibitors are a class of nonsteroidal anti-inflammatory agents formulated for direct cutaneous application
-
nih.gov
Topical phosphodiesterase-4 (PDE4) inhibitors are a class of nonsteroidal anti-inflammatory agents formulated for direct cutaneous application
-
fda.gov
They function by selectively inhibiting the intracellular PDE4 enzyme, which prevents the degradation of cyclic adenosine monophosphate (cAMP) and leads to elevated intracellular cAMP levels in immune cells and keratinocytes
-
pharmacytimes.com
They function by selectively inhibiting the intracellular PDE4 enzyme, which prevents the degradation of cyclic adenosine monophosphate (cAMP) and leads to elevated intracellular cAMP levels in immune cells and keratinocytes This signaling cascade downstream downregulates the production of key proinflammatory cytokines, chemokines, and mediators that drive chronic cutaneous inflammation Approved members of this class include crisaborole and roflumilast, which are primarily utilized for the manag...
-
nih.gov
This signaling cascade downstream downregulates the production of key proinflammatory cytokines, chemokines, and mediators that drive chronic cutaneous inflammation Approved members of this class include crisaborole and roflumilast, which are primarily utilized for the management of inflammatory dermatologic disorders, notably mild-to-moderate atopic dermatitis, plaque psoriasis, and seborrheic dermatitis
-
nih.gov
Approved members of this class include crisaborole and roflumilast, which are primarily utilized for the management of inflammatory dermatologic disorders, notably mild-to-moderate atopic dermatitis, plaque psoriasis, and seborrheic dermatitis
Sign in to follow this class
Following a drug class requires a free Physicians Office Resource account.